Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Claude Rwigema

Showing results (11-20 of 22) with videos related to

Pageof 3
Sort By:
American Journal of Clinical Oncology|June 23, 2017
Predictors of Local Recurrence in Patients With MyxofibrosarcomaBismarck Odei, Jean-Claude Rwigema, Frederick R Eilber, et al.
International Journal of Particle Therapy|November 1, 2021
Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute ToxicityRichard Choo, David W Hillman, Thomas Daniels, et al.
Frontiers in Oncology|January 2, 2026
Deep learning-based dose prediction for prostate cancer with empty bladder protocol: a framework for efficient and personalized radiotherapy planningByongsu Choi, Deepak K Shrestha, Albert Attia, et al.
International Journal of Radiation Oncology, Biology, Physics|November 25, 2022
Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate CancerRichard Choo, David W Hillman, Cecilia Mitchell, et al.
International Journal of Radiation Oncology, Biology, Physics|December 13, 2024
Five-Year Outcomes of Moderately Hypofractionated Proton Therapy Incorporating Elective Pelvic Nodal Irradiation for High-Risk Prostate CancerRichard Choo, David W Hillman, Cecilia Mitchell, et al.
Head & Neck|December 3, 2021
An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancersElizabeth B Jeans, Satomi Shiraishi, Gohar Manzar, et al.
The Prostate|July 5, 2022
A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of lifeWilliam W Wong, David W Hillman, Thomas B Daniels, et al.
Radiation Research|August 24, 2010
Intraesophageal manganese superoxide dismutase-plasmid liposomes ameliorates novel total-body and thoracic radiation sensitivity of NOS1-/- miceMalolan S Rajagopalan, Brandon Stone, Jean-Claude Rwigema, et al.
In Vivo (Athens, Greece)|January 3, 2012
Repopulation of the irradiation damaged lung with bone marrow-derived cellsMark E Bernard, Hyun Kim, Malolan S Rajagopalan, et al.
Advances in Radiation Oncology|February 27, 2023
Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical ProstatectomyBrady S Laughlin, Molly M Voss, Diego A S Toesca, et al.
Pageof 3

Showing results (11-20 of 22) with videos related to

Sort By:
Pageof 3
American Journal of Clinical Oncology|June 23, 2017
Predictors of Local Recurrence in Patients With MyxofibrosarcomaBismarck Odei, Jean-Claude Rwigema, Frederick R Eilber, et al.
International Journal of Particle Therapy|November 1, 2021
Proton Therapy of Prostate and Pelvic Lymph Nodes for High Risk Prostate Cancer: Acute ToxicityRichard Choo, David W Hillman, Thomas Daniels, et al.
Frontiers in Oncology|January 2, 2026
Deep learning-based dose prediction for prostate cancer with empty bladder protocol: a framework for efficient and personalized radiotherapy planningByongsu Choi, Deepak K Shrestha, Albert Attia, et al.
International Journal of Radiation Oncology, Biology, Physics|November 25, 2022
Late Toxicity of Moderately Hypofractionated Intensity-Modulated Proton Therapy Treating the Prostate and Pelvic Lymph Nodes for High-Risk Prostate CancerRichard Choo, David W Hillman, Cecilia Mitchell, et al.
International Journal of Radiation Oncology, Biology, Physics|December 13, 2024
Five-Year Outcomes of Moderately Hypofractionated Proton Therapy Incorporating Elective Pelvic Nodal Irradiation for High-Risk Prostate CancerRichard Choo, David W Hillman, Cecilia Mitchell, et al.
Head & Neck|December 3, 2021
An comparison of acute toxicities and patient-reported outcomes between intensity-modulated proton therapy and volumetric-modulated arc therapy after ipsilateral radiation for head and neck cancersElizabeth B Jeans, Satomi Shiraishi, Gohar Manzar, et al.
The Prostate|July 5, 2022
A Phase II prospective study of hypofractionated proton therapy of prostate and pelvic lymph nodes: Acute effects on patient-reported quality of lifeWilliam W Wong, David W Hillman, Thomas B Daniels, et al.
Radiation Research|August 24, 2010
Intraesophageal manganese superoxide dismutase-plasmid liposomes ameliorates novel total-body and thoracic radiation sensitivity of NOS1-/- miceMalolan S Rajagopalan, Brandon Stone, Jean-Claude Rwigema, et al.
In Vivo (Athens, Greece)|January 3, 2012
Repopulation of the irradiation damaged lung with bone marrow-derived cellsMark E Bernard, Hyun Kim, Malolan S Rajagopalan, et al.
Advances in Radiation Oncology|February 27, 2023
Preliminary Analysis of a Phase II Trial of Stereotactic Body Radiation Therapy for Prostate Cancer With High-Risk Features After Radical ProstatectomyBrady S Laughlin, Molly M Voss, Diego A S Toesca, et al.
Pageof 3